Magnesium Treatment in Hypoparathyroidism

This study is currently recruiting participants.

Verified by University of Tartu, March 2009

First Received: January 15, 2009 Last Updated: March 6, 2009 History of Changes

Sponsored by:	University of Tartu
Information provided by:	University of Tartu
ClinicalTrials.gov Identifier:	NCT00824226

Purpose

Study hypothesis: supplementary magnesium may influence the blood calcium level in treated hypoparathyroid patients. Patients will be treated with supplementary magnesium (350 mg/day) for 3 weeks. Calcium and other relevant blood parameters will be measured before the treatment, at the end of treatment and 2 weeks after stopping treatment.

Condition	Intervention
Hypoparathyroidism	Dietary Supplement: magnesium

MedlinePlus related topics: Calcium

Drug Information available for: Magnesium

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Open Label, Single Group Assignment
Official Title:	Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients

Further study details as provided by University of Tartu:

Primary Outcome Measures:

Calcium level at the end of magnesium treatment compared to pretreatment level [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Calcium level after stopping treatment compared to the level at the end of magnesium treatment [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment:	10
Study Start Date:	January 2009
Estimated Study Completion Date:	December 2010
Estimated Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)

Intervention Details:

magnesium 350 mg tablets once a day for 3 weeks

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

primary or secondary hypoparathyroidism
treatment with calcium plus vitamin D analogue
ionized calcium 1,0-1,29 mmol/L
magnesium level 0,7-1,05 mmol/L
TSH 0.1- 10 imU/L

Exclusion Criteria:

any other disease known to influence plasma Ca level
pregnancy
creatinine > 150 microM/L
patient has used supplementary magnesium within 2 previous months

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00824226

Contacts

Contact: Vallo Volke, MD, PhD

+372 7 374338

vallo.volke@ut.ee

Locations

Estonia
Tartu University Hospital	Recruiting
Tartu, Estonia, 50406
Contact: Vallo Volke, MD, PhD vallo.volke@ut.ee

Sponsors and Collaborators

University of Tartu

Investigators

Principal Investigator:

Vallo Volke, MD, PhD

University of Tartu, Institute of Physiology

More Information

No publications provided

Responsible Party:	University of Tartu ( Dr. Vallo Volke )
Study ID Numbers:	UT296
Study First Received:	January 15, 2009
Last Updated:	March 6, 2009
ClinicalTrials.gov Identifier:	NCT00824226 History of Changes
Health Authority:	Estonia: The State Agency of Medicine

Keywords provided by University of Tartu:

primary hypoparathyroidism
secondary hypoparathyroidism
magnesium

Study placed in the following topic categories:

Calcium, Dietary
Parathyroid Diseases
Neoplasm Metastasis

Endocrine System Diseases
Endocrinopathy
Hypoparathyroidism

Additional relevant MeSH terms:

Parathyroid Diseases
Endocrine System Diseases
Hypoparathyroidism

ClinicalTrials.gov processed this record on May 07, 2009